A randomized, double-blind, parallel-group, multicenter Phase 2b study to assess the efficacy and safety of two different doses of vilaprisan (BAY 1002670) versus placebo in women with symptomatic endometriosis

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 19 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vilaprisan (Primary)
Indications Endometriosis
Focus Therapeutic Use
Acronyms VILLENDO
Sponsors Bayer; Bayer HealthCare

Most Recent Events

19 Jan 2021 Status changed from completed to discontinued. Reason the study was stopped: Due to a change in the development program, the study was closed prematurely.
21 Oct 2020 Status changed from active, no longer recruiting to completed.
24 Apr 2020 Planned End Date changed from 30 Jun 2020 to 30 Sep 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight